XML 44 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Xcede Technologies, Inc. Joint Venture (Details) - USD ($)
1 Months Ended 9 Months Ended
Apr. 30, 2019
Nov. 30, 2016
Jun. 30, 2019
Cook Biotech Inc [Member]      
Line of Credit Facility, Maximum Borrowing Capacity     $ 1,500,000
Long-term Line of Credit     $ 500,000
Noncontrolling Interest [Member]      
Debt Conversion, Original Debt, Amount   $ 3,100,000  
Debt Conversion, Converted Instrument, Shares Issued   3,100,000  
Xcede Technologies, Inc [Member]      
Debt Instrument, Interest Rate, Stated Percentage   5.00%  
Committed Investment In Cash   $ 1,200,000  
Debt Conversion, Converted Instrument, Shares Issued   3,055,551  
Capital Stock Financing Discount Percentage   20.00%  
Noncontrolling Interest, Description     Noncontrolling interest represents the value of the Series A Preferred and common stock not owned by DBM plus 17% of cumulative losses of Xcede based on the 17% common stock ownership held by noncontrolling interests.
Equity Method Investment, Ownership Percentage     63.00%
Dynasil Biomedical [Member]      
Debt Conversion, Original Debt, Amount   $ 2,400,000  
Debt Conversion, Converted Instrument, Shares Issued   2,338,569  
Phase I SBIR [Member]      
Application Grant Value $ 225,000    
External Funding [Member] | Convertible Debt [Member]      
Debt Conversion, Original Debt, Amount   $ 5,200,000  
Series B Preferred Stock [Member]      
Preferred Stock, Liquidation Preference Per Share     $ 1.27
Preferred Stock, Liquidation Preference, Value     $ 1,500,000
Series A Preferred Stock [Member]      
Preferred Stock, Liquidation Preference Per Share     $ 1.016
Preferred Stock, Liquidation Preference, Value     $ 5,500,000
Series A Preferred Stock [Member] | Dynasil Biomedical [Member]      
Preferred Stock, Liquidation Preference, Value     $ 2,400,000